Expanding the phenotype of intellectual disability caused by HIVEP2 variants.


Journal

American journal of medical genetics. Part A
ISSN: 1552-4833
Titre abrégé: Am J Med Genet A
Pays: United States
ID NLM: 101235741

Informations de publication

Date de publication:
09 2019
Historique:
received: 24 01 2019
revised: 09 04 2019
accepted: 01 06 2019
pubmed: 18 6 2019
medline: 4 8 2020
entrez: 18 6 2019
Statut: ppublish

Résumé

De novo pathogenic variants in the human immunodeficiency virus enhancer type I binding protein 2 (HIVEP2) gene, a large transcription factor predominantly expressed in the brain have previously been associated with intellectual disability (ID) and dysmorphic features in nine patients. We describe the phenotype and genotype of two additional patients with novel de novo pathogenic HIVEP2 variants, who have previously unreported features, including hyperphagia and Angelman-like features. Exome sequencing was utilized in the investigation of the patients who had previously incurred a rigorous genetic workup for their neurodevelopmental delay, and in whom no genetic cause had been detected. Information pertaining to phenotype and genotype for new patients was collated along with data from previous reports, showing that the phenotypic spectrum of patients with HIVEP2 variants is broader than first noted. Additional characteristics are: an increased body mass index; and features of Angelman-like syndromes including: ID, limited speech, post-natal microcephaly, and hypotonia. Dysmorphic features vary between patients. As yet, no clear association between the type of gene aberration and phenotype can be concluded. HIVEP2-related ID needs to be considered in the differential diagnosis of patients with Angelman-like phenotypes and hyperphagia, and whole-exome sequencing should be considered in the genetic diagnostic armamentarium for patients with ID of inconclusive etiology.

Identifiants

pubmed: 31207095
doi: 10.1002/ajmg.a.61271
doi:

Substances chimiques

DNA-Binding Proteins 0
Transcription Factors 0
HIVEP2 protein, human 148770-78-9

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1872-1877

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Heidi Goldsmith (H)

Hunter Genetics, Waratah, New South Wales, Australia.

Anna Wells (A)

University of Newcastle, Callaghan, New South Wales, Australia.

Maria J N Sá (MJN)

Department of Human Genetics, Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands.

Mark Williams (M)

Mater Research Institute, The University of Queensland, Woolloongabba, Queensland, Australia.
Genetic Pathology, Mater Pathology, South Brisbane, Queensland, Australia.

Helen Heussler (H)

Child Development Program, Queensland Children's Hospital, South Brisbane, Queensland, Australia.
Child Health Research Centre, The University of Queensland, South Brisbane, Queensland, Australia.

Melissa Buckman (M)

Genetic Counselling Service, Tamworth, New South Wales, Australia.

Rolph Pfundt (R)

Department of Human Genetics, Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands.

Bert B A de Vries (BBA)

Department of Human Genetics, Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands.

Himanshu Goel (H)

Hunter Genetics, Waratah, New South Wales, Australia.
University of Newcastle, Callaghan, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH